The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trial—A randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer.
 
Sandro Pignata
Honoraria - AstraZeneca; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Roche Pharma AG
Research Funding - AstraZeneca; Janssen-Cilag; Roche Pharma AG
 
Giovanni Scambia
No Relationships to Disclose
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Roche Pharma AG
Research Funding - PharmaMar; Roche Pharma AG
 
Ugo De Giorgi
No Relationships to Disclose
 
Maria Ornella Nicoletto
No Relationships to Disclose
 
Rossella Lauria
No Relationships to Disclose
 
Anna Maria Mosconi
No Relationships to Disclose
 
Cosimo Sacco
No Relationships to Disclose
 
Claudia Omarini
No Relationships to Disclose
 
Pierosandro Tagliaferri
No Relationships to Disclose
 
Gabriella Ferrandina
No Relationships to Disclose
 
Saverio Cinieri
Speakers' Bureau - AstraZeneca; Ipsen; Italfarmaco; Lilly; Novartis; Roche Pharma AG
Research Funding - AstraZeneca; Novartis; Roche Pharma AG
Travel, Accommodations, Expenses - Bayer; Ipsen; Novartis; Roche Pharma AG
 
Carmela Pisano
No Relationships to Disclose
 
Sabrina Chiara Cecere
No Relationships to Disclose
 
Marilena Di Napoli
No Relationships to Disclose
 
Vanda Salutari
No Relationships to Disclose
 
Maria Carmela Piccirillo
No Relationships to Disclose
 
Gennaro Daniele
Honoraria - Bayer Schering Pharma
 
Ciro Gallo
No Relationships to Disclose
 
Francesco Perrone
Honoraria - Amgen; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Roche; Roche
Patents, Royalties, Other Intellectual Property - THE MITO 16 programme partial funding; The MITO-11 trial funding from GSK; The STAD-1 partial funding from AMGEN
Travel, Accommodations, Expenses - Bayer Schering Pharma; Bayer Schering Pharma; Roche